Gastric cancer detection based on cell-free DNA in blood: A systematic review and meta-analysis

Abstract

Objective: Screening and early diagnosis of gastric cancer (GC) are crucial for improved prognosis. However, gastroscopic screening is not feasible in large populations due to its high cost and invasive nature. The detection of circulating cell-free DNA (cfDNA) provides an attractive minimally-invasive alternative for screening of GC. In this systematic review and meta-analysis, we evaluate the diagnostic value of cfDNA-based markers for GC, including the detection of total concentration, mutations, and methylation alterations.

Methods: We performed a systematic search of four literature databases (PubMed, Embase, Web of Science, and Cochrane Library) for articles published before November 2022. The revised tool for the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) was used to evaluate the quality of included studies. PROSPERO registration number: CRD42021210830.

Results: A total of 15 original articles involving 2849 individuals were included in this meta-analysis, comprising five studies on concentration, nine studies on methylation alterations, and one study on mutation biomarkers of cfDNA. Among these studies, seven selected early-stage GC subjects. For the diagnoses of overall stages and early-stage GC, the pooled sensitivities with 95% confidence interval were 0.74 (0.66–0.82) and 0.64 (0.51–0.76), and the pooled specificities were 0.92 (0.84–0.96) and 0.94 (0.87–0.98) with summary areas under the curve (SAUCs) of 0.89 (0.86–0.91) and 0.86 (0.83–0.89), respectively.

Conclusions: This meta-analysis suggests that cfDNA-based biomarkers show diagnostic value for GC early detection.

Keywords

circulating cell-free DNA / early diagnosis / gastric cancer / liquid biopsy

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.

[2] Li Y, Feng A, Zheng S, Chen C, Lyu J. Recent estimates and predictions of 5-year survival in patients with gastric cancer: a model-based period analysis. Cancer Control. 2022;29:10732748221099227.

[3] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics. CA Cancer J Clin. 2023;73:17-48.

[4] Cenitagoya GF, Bergh CK, Klinger-Roitman J. A prospective study of gastric cancer. ‘Real’ 5-year survival rates and mortality rates in a country with high incidence. Dig Surg. 1998;15:317-322.

[5] Suzuki H, Oda I, Abe S, et al. High rate of 5-year survival among patients with early gastric cancer undergoing curative endoscopic submucosal dissection. Gastric Cancer. 2016;19:198-205.

[6] Huang Ya-K, Yu J-C, Kang W-M, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS One. 2015;10:e0142080.

[7] Yu G, Wang GX, Wang HG, Mo FF, Tang BB. The value of detecting pepsinogen and gastrin-17 levels in serum for pre-cancerous lesion screening in gastric cancer. Neoplasma. 2019;66:637-640.

[8] Kim K, Shin DG, Park MK, et al. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res. 2014;86:136-142.

[9] Xiangxiang Li, C C, Lin W, Baoli H, Qunxin P, Jinfang SHI. Significance of content and integrity changes of peripheral blood cell-free DNA in diagnosis and treatment in gastric cancer. Cancer Res Prev Treat. 2017;44:118-123.

[10] Park KUn, Lee HE, Park DoJ, et al. MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis. Clin Chem Lab Med. 2009;47:530-536.

[11] Wu X, Gu Y, Jing R, Zhan L, Ju S, Zhang J. Serum cell free DNA by branched DNA in patients with gastric cancer. Int J Clin Exp Med Int J Clin. 2016;9(6):11175-11183. Exp Med 2016.

[12] Kim YS. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett. 2012;3:921-926.

[13] Esposito A, Criscitiello C, Trapani D, Curigliano G. The emerging role of “liquid biopsies,” circulating tumor cells, and circulating cell-free tumor DNA in lung cancer diagnosis and identification of resistance mutations. Curr Oncol Rep. 2017;19(1):1.

[14] Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37:646-650.

[15] Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415.

[16] Lanata CM, Chung SA, Criswell LA. DNA methylation 101: what is important to know about DNA methylation and its role in SLE risk and disease heterogeneity. Lupus Sci Med. 2018;5:e000285.

[17] Whiting PF. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529-536.

[18] Anderson WF, Rabkin CS, Turner N, Fraumeni JF, Rosenberg PS, Camargo MC. The changing face of noncardia gastric cancer incidence among US non-Hispanic Whites. J Natl Cancer Inst. 2018;110:608-615.

[19] Cao C-Qi, Chang L, Wu Qi. Circulating methylated Septin 9 and ring finger protein 180 for noninvasive diagnosis of early gastric cancer. Transl Cancer Res. 2020;9:7012-7021.

[20] Chen X, Gole J, Gore A, et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nature Commun. 2020;11:3475.

[21] Hideura E, Suehiro Y, Nishikawa J, et al. Blood free-circulating DNA testing of methylated RUNX3 is useful for diagnosing early gastric cancer. Cancers. 2020;12:789.

[22] Kandimalla R, Xu J, Link A, et al. EpiPanGI Dx: a cell-free DNA methylation fingerprint for the early detection of gastrointestinal cancers. Clin Cancer Res. 2021;27:6135-6144.

[23] Ren J, Lu P, Zhou X, et al. Genome-scale methylation analysis of circulating cell-free DNA in gastric cancer patients. Clin Chem. 2022;68:354-364.

[24] Saliminejad K, et al. Methylation analysis of P16, RASSF1A, RPRM, and RUNX3 in circulating cell-free DNA for detection of gastric cancer: a validation study. Avicenna J Med Biotechnol. 2020;12:99-106.

[25] Wei K-L, Chou J-L, Chen Y-C, et al. Methylomics analysis identifies a putative STAT3 target, SPG20, as a noninvasive epigenetic biomarker for early detection of gastric cancer. PLoS One. 2019;14:e0218338.

[26] Yang Q, Gao J, Xu L, Zeng Z, Sung JJY, Yu J. Promoter hypermethylation of BCL6B gene is a potential plasma DNA biomarker for gastric cancer. Biomarkers. 2013;18:721-725.

[27] Zhang X, Zhang X, Sun B, et al. Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer. Oncol Lett. 2014;8:1745-1750.

[28] Cohen JD, Li Lu, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359:926-930.

[29] Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446-451.

[30] Fiala C, Diamandis EP. Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018;16:166.

[31] Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16:409-424.

[32] Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570:385-389.

[33] Kato S, Okamura R, Baumgartner JM, et al. Analysis of circulating tumor DNA and clinical correlates in patients with esophageal, gastroesophageal junction, and gastric adenocarcinoma. Clin Cancer Res. 2018;24:6248-6256.

[34] Tomeva E, Switzeny OJ, Heitzinger C, Hippe B, Haslberger AG. Comprehensive approach to distinguish patients with solid tumors from healthy controls by combining androgen receptor mutation p.H875Y with cell-free DNA methylation and circulating miRNAs. Cancers (Basel). 2022;14.

[35] Varkalaite G, Forster M, Franke A, Kupcinskas J, Skieceviciene J. Liquid biopsy in gastric cancer: analysis of somatic cancer tissue mutations in plasma cell-free DNA for predicting disease state and patient survival. Clin Transl Gastroenterol. 2021;12:e00403.

[36] Fan X-H, Zhang Y, Wang P, et al. A noninvasive multianalytical approach establishment for risk assessment and gastric cancer screening. Int J Cancer. 2024;154:1111-1123.

[37] Kim J, Cho YAe, Choi WJ, Jeong SH. Gene-diet interactions in gastric cancer risk: a systematic review. World J Gastroenterol. 2014;20:9600-9610.

RIGHTS & PERMISSIONS

2024 2024 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.